An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Arcturus Therapeutics Holdings Inc. will release its financial results for the first quarter of 2024 on May 8, 2024, focusing on mRNA medicines for infectious diseases and rare liver and respiratory diseases.
Arcturus Therapeutics Holdings Inc. pubblicherà i suoi risultati finanziari per il primo trimestre del 2024 l'8 maggio 2024, concentrandosi su medicine mRNA per malattie infettive e malattie rare del fegato e respiratorie.
Arcturus Therapeutics Holdings Inc. divulgará sus resultados financieros para el primer trimestre de 2024 el 8 de mayo de 2024, centrando su atención en medicamentos de mRNA para enfermedades infecciosas y enfermedades raras del hígado y respiratorias.
Arcturus Therapeutics Holdings Inc.는 2024년 5월 8일에 2024년 첫 분기의 재무 결과를 발표할 예정이며, 감염병 및 희귀 간 및 호흡기 질환을 위한 mRNA 의약품에 중점을 둘 것입니다.
Arcturus Therapeutics Holdings Inc. publiera ses résultats financiers pour le premier trimestre de 2024 le 8 mai 2024, en se concentrant sur les médicaments à ARNm pour les maladies infectieuses et les maladies rares du foie et respiratoires.
Arcturus Therapeutics Holdings Inc. wird am 8. Mai 2024 seine Finanzergebnisse für das erste Quartal 2024 veröffentlichen, wobei der Schwerpunkt auf mRNA-Medikamenten für Infektionskrankheiten und seltene Leber- und Atemwegserkrankungen liegt.
Positive
None.
Negative
None.
SAN DIEGO--(BUSINESS WIRE)--
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that it will release its financial results for the quarter ended March 31, 2024 after the market close on Wednesday, May 8 and will also host a conference call and webcast at 4:30 pm Eastern Time on May 8, 2024.
Arcturus Therapeutics First Quarter 2024 Earnings Conference Call
Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a global mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR® mRNA Technology (sa-mRNA) and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus developed the first self-amplifying messenger RNA (sa-mRNA) COVID vaccine (Kostaive®) in the world to be approved. Arcturus has an ongoing global collaboration for innovative mRNA vaccines with CSL Seqirus, and a joint venture in Japan, ARCALIS, focused on the manufacture of mRNA vaccines and therapeutics. Arcturus’ pipeline includes RNA therapeutic candidates to potentially treat ornithine transcarbamylase deficiency and cystic fibrosis, along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics. Arcturus’ technologies are covered by its extensive patent portfolio (over 400 patents and patent applications in the U.S., Europe, Japan, China, and other countries). For more information, visit www.ArcturusRx.com. In addition, please connect with us on Twitter and LinkedIn.
founded in 2013 and based in san diego, calif., arcturus therapeutics is poised to become an industry leader in the application of rnai technologies for the treatment of disease and improved quality of life. the company’s aim is to develop breakthrough technology and novel therapeutics for rare diseases for which there is no adequate treatment. backed by a management team with extensive experience in the discovery and development of therapeutic modalities, arcturus is on the forefront of research and development of nanoparticle sirna drug delivery systems.
